Fly News Breaks for November 12, 2019
Nov 12, 2019 | 11:25 EDT
Piper Jaffray analyst Joseph Catanzaro lowered his price target for Ocular Therapeutix to $5 from $8 following the company's Q3 earnings, which included ~$300,000 in Dextenza sales in its initial quarter. In a research note to investors, Catanzaro says he views the next ~6 months as crucial as it should provide a better sense of Dextenza's long-term opportunity, whether the AC trial is positive and whether cash runway can be further extended. He keeps an Overweight rating on the shares.
News For OCUL From the Last 2 Days
There are no results for your query OCUL